Reportlinker Adds Small Molecule Kinase Inhibit...(The Truth Behind Inadequate Reimbursemen...)

Manufacturers Find Risk-Sharing, Rebating, & Contracting As Effective Antidotes II-9

Financial-based Contracts II-10

Performance-based Contracts II-10

Reimbursements Issues in UK II-10

On Cards: Reimbursement for Pfizer's Sutent in UK II-10

Reimbursement for GlaxoSmithKline's Tyverb Hits a Roadblock in UK II-10

Reimbursements Issues in the United States II-10

Medicare Shifts Oral Anti Cancer Drugs to Higher Drug Formulary Tiers II-10

Implications for the Patient II-11

Table 4: Oral Anticancer Drugs Covered in Medicare Part D Plans (2009): Percentage Share Breakdown of Plans, Which Require Prior Authorization, & Plans, Which Have Quantity Limits, by Drug Brand (includes corresponding Graph/Chart) II-12

Table 5: Oral Anticancer Drugs Covered in Medicare Part D Plans (2009): Breakdown of Cost Sharing Range by Drug Brand II-12

Table 6: Placement of Select Oral Anticancer Drugs in the Drug Tier System Covered in Medicare Part D Plans for the Year 2009) II-13

Transition of Oral Anti-Cancer Drugs to Higher Cost Sharing

Tiers: Gleevec A Case in Point: II-13

Table 7: Percentage Breakdown of Beneficiaries Prescribed Gleevec and Covered Under Standalone Prescription Drug Plans (PDPs) by Tier For Years 2006 through 2009 (includes corresponding Graph/Chart) II-13

Table 8: Change in Percentage of Co-insurance Amount for Leading Oral Cancer Therapies Under Standalone Prescription Drug Plans (PDPs) (During 2006 to 2009) - For Gleevec,

Tarceva, Sutent, and Tykerb (includes corresponding Graph/Chart) II-14

Emergence of Newer Side effects: An Area of Concern for Modern pKis II-14

Hsp90 Inhibitors: Hope for Cancer Patients Resistant to Kinase Inhibitor Drugs II-14

Noteworthy Issues Related to Major Drugs: An Evaluation of
'/>"/>